Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid ...
Wells Fargo analyst Yanan Zhu maintains Affimed (NASDAQ:AFMD) with a Overweight and lowers the price target from $30 to $25.
Cantor Fitzgerald analyst Li Watsek reiterates Affimed (NASDAQ:AFMD) with a Overweight.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Affimed (NASDAQ:AFMD) with a Buy and raises the price targe...
Affimed (NASDAQ:AFMD) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.67) by 10...
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...
